Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Total Current Liabilities (2020 - 2025)

Mereo BioPharma (MREO) has disclosed Total Current Liabilities for 5 consecutive years, with $4.3 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities fell 68.93% to $4.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.3 million through Dec 2025, down 68.93% year-over-year, with the annual reading at $4.3 million for FY2025, 68.93% down from the prior year.
  • Total Current Liabilities for Q4 2025 was $4.3 million at Mereo BioPharma, down from $6.0 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $16.9 million in Q4 2021, with the low at $4.3 million in Q4 2025.
  • Average Total Current Liabilities over 4 years is $10.6 million, with a median of $10.2 million recorded in 2023.
  • The sharpest move saw Total Current Liabilities soared 49.48% in 2021, then plummeted 68.93% in 2025.
  • Over 4 years, Total Current Liabilities stood at $16.9 million in 2021, then crashed by 43.89% to $9.5 million in 2023, then surged by 45.98% to $13.8 million in 2024, then crashed by 68.93% to $4.3 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $4.3 million, $6.0 million, and $7.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.